Abstract:Modern drug design aims to discover novel lead compounds with attractable chemical profiles to enable further exploration of the intersection of chemical space and biological space. Identification of small molecules with good ligand efficiency, high activity, and selectivity is crucial toward developing effective and safe drugs. However, the intersection is one of the most challenging tasks in the pharmaceutical industry, as chemical space is almost infinity and continuous, whereas the biological space is very limited and discrete. This bottleneck potentially limits the discovery of molecules with desirable properties for lead optimization. Herein, we present a new direction leveraging posttranslational modification (PTM) protein isoforms target space to inspire drug design termed as "Post-translational Modification Inspired Drug Design (PTMI-DD)." PTMI-DD aims to extend the intersections of chemical space and biological space. We further rationalized and highlighted the importance of PTM protein isoforms and their roles in various diseases and biological functions. We then laid out a few directions to elaborate the PTMI-DD in drug design including discovering covalent binding inhibitors mimicking PTMs, targeting PTM protein isoforms with distinctive binding sites from that of wild-type counterpart, targeting protein-protein interactions involving PTMs, and hijacking protein degeneration by ubiquitination for PTM protein isoforms. These directions will lead to a significant expansion of the biological space and/or increase the tractability of compounds, primarily due to precisely targeting PTM protein isoforms or complexes which are highly relevant to biological functions. Importantly, this new avenue will further enrich the personalized treatment opportunity through precision medicine targeting PTM isoforms.

Targeted Protein Posttranslational Modifications by Chemically Induced Proximity for Cancer Therapy

Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications

Advances of Proteomics in Novel PTM Discovery: Applications in Cancer Therapy

Targeting PTPs with small molecule inhibitors in cancer treatment

PROTACs: Novel tools for improving immunotherapy in cancer

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

Protein post-translational modifications in the regulation of cancer hallmarks

Harmony of Protein Tags and Chimeric Molecules Empowers Targeted Protein Ubiquitination and Beyond

Targeting micro-environmental pathways by PROTACs as a therapeutic strategy

Targeted protein degrader development for cancer: advances, challenges, and opportunities

Recent advancements in targeted protein knockdown technologies—emerging paradigms for targeted therapy

Advances in post-translational modifications of proteins and cancer immunotherapy

Small Molecule PROTACs: an Emerging Technology for Targeted Therapy in Drug Discovery

Drug design targeting active posttranslational modification protein isoforms

[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy]

Pan-cancer Analysis of Post-Translational Modifications Reveals Shared Patterns of Protein Regulation.

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination.

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future